# Anbio Biotechnology share price today (Anbio Biotechnology, NNNN)

> Anbio Biotechnology's earnings have grown faster than its share price. Earnings per share grew +161.3% in a year while the price moved −78.8%. NNNN · Healthcare · Medical Instruments & Supplies · data as of 3 November 2026. Page: https://www.sectoralpha.in/us/stocks/nnnn

Sector Alpha also publishes a daily newsletter that explains one Indian stock at a time: https://newsletter.sectoralpha.in/?utm_source=sectoralpha&utm_medium=ai_text&utm_campaign=llms

## Key numbers

- Price: $3.58 (−78.8% in a year)
- P/E: 24.4×, against its own history
- Revenue (Dec 2025): $4.1 M (+73.9% on a year ago)
- Profit (Dec 2025): $2.6 M
- Operating margin: 59.1% (+127.7 points on a year ago)
- ROE: 21%, FY25

The main question: profits are rising, but only −34% of the last 3 years' profit came in as cash from operations. The gap between reported profit and actual cash is the thing to watch. ## What is the Anbio Biotechnology share price today? Anbio Biotechnology's share price was $3.58 at the close on 3 November 2026. That is 79.0% below its average price over the last 200 trading days. In the last 52 weeks it traded between $3 and $37, and at that close it sat 1% of the way up from that low. Over the past 13 weeks it has done worse than the S&P 500, and it has been behind for 23 weeks running. Over the last 1 year the share price moved −93% while the S&P 500 moved +21%, so it is behind the index over that whole period. It was last ahead over 13 weeks in the week of 29 May 2026. The chart above shows the 13-week comparison for every week. This page treats a rise as over when the price closes below its 200-day average on two Fridays in a row. ## What dividend does Anbio Biotechnology pay? Anbio Biotechnology pays no dividend. In the last 8 reported quarters it declared no dividend per share, so there is no payout history to chart and no yield to show. Companies like this usually keep their earnings in the business, so the cash-flow sections show where that cash goes. ## Which stock lists is Anbio Biotechnology on? Anbio Biotechnology is not in the Nasdaq 100, the S&P 500 or the Dow Jones 30, and is not on the US tech stocks list. ## Is Anbio Biotechnology profitable? Anbio Biotechnology earned $2.6 M of net profit in the Dec 2025 quarter. Full-year FY25 profit was $6.4 M. Over 4 years profit has grown 26.1% a year on average. That is 64.2% of the quarter's revenue. The same quarter a year earlier earned $733 K. 2 of the last 8 reported quarters were loss-making. For the full year, FY25 profit was $6.4 M (+169.8% on the year before). On average over the last four quarters, profit changed −41.6% and revenue +26.9%. Profit is growing slower than sales: rising costs are taking part of the growth. ## How much revenue does Anbio Biotechnology make, and is it growing? Anbio Biotechnology reported $4.1 M of revenue in the Dec 2025 quarter, +73.9% on the same quarter a year earlier. Over 4 years it has grown 18.2% a year on average. The last full year, FY25, came in at $8.6 M. FY25 revenue was $8.6 M, +5.6% on the year before. Recent pace: the last four quarters grew +26.9% on average, against 18.2% a year over the longer run, so this year is growing faster than its own long-run rate. ## How much of every $100 of sales does Anbio Biotechnology keep? Anbio Biotechnology's operating margin was 59.1% in the Dec 2025 quarter, 127.7 percentage points higher than the same quarter a year ago. Its latest full-year margin is the highest it has ever reported. Over the last four quarters it has moved +44.3 percentage points. Across 5 years it has been between 24.4% and 66.7%. The latest quarter is within that range. Why the margin moved: operating margin changed +44.3 percentage points on the year while gross margin changed +38.7 points. So the gain came mostly from the gross margin, which means input costs and prices charged. When margins are at a record, every ratio built on profit looks better than usual, so watch whether they hold. ## Is Anbio Biotechnology's profit turning into cash? Over the last 3 years Anbio Biotechnology's operations used more cash than they brought in, so cash conversion was −34%, a gap worth watching. In FY25 its operations used $6.7 M of cash, against $6.4 M of profit. Cash-flow figures here are yearly, because quarterly cash statements are not published, so this section changes once a year. Why: the cash figure is clear, but the day counts behind it are not in our data, so we show it without guessing the reason. What to look at next: no single use of cash stands out. The next section checks both the cash tied up in daily operations and the spending on assets. ## Where does Anbio Biotechnology's cash go? Anbio Biotechnology does not report the customer, stock and supplier day counts a cash cycle needs, so this section looks at its spending on assets instead. Nothing is estimated in place of the missing day counts, so no cash-cycle chart is drawn. In short: neither the daily cycle nor new spending is soaking up the cash, so the picture is fairly clean. ## What is Anbio Biotechnology's P/E ratio, and how does it compare with its own history? Anbio Biotechnology's P/E is 24.4×, with too little history to compare. This compares the share price with the company’s own past. It does not say what the business is worth. Why the multiple is where it is: over the past year earnings per share moved +161.3% while the price moved −78.8%. Earnings did better than the price, which pulled the multiple down within its own range. In short: there is too little history to say whether the multiple is high or low for this company, so the earnings trend underneath matters more than the multiple. ## Is the Anbio Biotechnology business getting better or worse? Anbio Biotechnology's business trend cannot be read yet. There are fewer than eight usable quarters of growth figures, so there is not enough history to read the trend. This is based on 6 quarters of 1 measure, with some gaps. Why it matters: with too little history, we say so rather than guess a direction. One or more growth lines have an extreme jump caused by comparing with a near-zero or loss-making quarter. Those jumps are capped before reading and drawn at the edge of the chart, so one odd quarter does not decide the result. The return figures here are yearly, not quarterly. They show level and direction only; they can support the growth lines but never decide the reading alone. There are fewer than eight usable quarters, so this page does not guess a direction from so little history. ## How much does Anbio Biotechnology earn on its capital? Anbio Biotechnology earned a ROE of 21% in FY25. That is up from a low of 14% in FY24. Its return on capital used (ROIC) is left out: on sales this small it reads 102%, a number that says nothing useful about the business. It comes from a 74.0% net margin and 0.29× asset turnover (sales divided by assets). Why the return is what it is (FY25): a 74.0% net margin × 0.29× asset turnover × 1.00× leverage (assets divided by equity) ≈ 21.5% on equity. The margin does most of the work; borrowing plays a small part, so this return is earned, not borrowed. ## Does Anbio Biotechnology have too much debt? A history of Anbio Biotechnology's borrowings is not in our data. ## What is the Anbio Biotechnology shareholding pattern? 0.1% of Anbio Biotechnology's tradable shares are in short positions, which are bets that the price will fall, so very few traders are betting against this stock. At normal trading volumes, closing those positions would take about 0.2 days. US companies do not publish a quarter-by-quarter list of owners, so this page uses short interest instead. It is a single reading at one point in time; we do not have its history. Why it is at this level: the figure does not say who holds the short positions or why, so we show the level without guessing the story. ## How far is Anbio Biotechnology from balance-sheet trouble? For Anbio Biotechnology, the Z-score is not available, so we say so rather than guess one. It estimates how far the balance sheet is from trouble; it is not a forecast of failure. The debt, cash-flow and return sections show the balance-sheet figures we do have, each with its own date. ## How does Anbio Biotechnology rank in its industry? There is no score against its industry: Anbio Biotechnology is not among the largest members shown in this industry comparison for Medical Instruments & Supplies. The score ranks a company within its industry: each measure is scored against the other members. Without that group there is no score, so none is shown. ## Which companies is Anbio Biotechnology compared with? No sector comparison is shown here, not among the largest members shown in this industry comparison. ## Which companies are close to Anbio Biotechnology in size? Anbio Biotechnology is the 38th largest of 38 Medical Instruments & Supplies companies on Sector Alpha by market value (scores of 3 November 2026). Just above it: AngioDynamics, Inc., Embecta Corp., Sanara MedTech Inc., OraSure Technologies, Inc., Utah Medical Products, Inc. and Pro-Dex, Inc. It is the smallest. ### Medical Instruments & Supplies companies close in size

1. [AngioDynamics, Inc.](https://www.sectoralpha.in/us/stocks/ango) $493 million
2. [Embecta Corp.](https://www.sectoralpha.in/us/stocks/embc) $344 million
3. [Sanara MedTech Inc.](https://www.sectoralpha.in/us/stocks/smti) $296 million
4. [OraSure Technologies, Inc.](https://www.sectoralpha.in/us/stocks/osur) $243 million
5. [Utah Medical Products, Inc.](https://www.sectoralpha.in/us/stocks/utmd) $222 million
6. [Pro-Dex, Inc.](https://www.sectoralpha.in/us/stocks/pdex) $193 million
7. Anbio Biotechnology $157 million

[All 38 Medical Instruments & Supplies companies, largest first](https://www.sectoralpha.in/us/sectors/medical-instruments-supplies#all-companies)

## What else do people ask about Anbio Biotechnology? ### What were Anbio Biotechnology's latest quarterly results? Anbio Biotechnology reported revenue of $4.1 M and net profit of $2.6 M for the Dec 2025 quarter. Earnings per share were $0.06. The operating margin was 59.1%, 127.7 percentage points higher than a year earlier (as of 3 November 2026). ### What is Anbio Biotechnology's market cap? Anbio Biotechnology's market capitalisation is $157 M at a stock price of $3.58. Market cap is the share price times the number of shares, so it changes whenever the price moves (as of 3 November 2026). ### How is Anbio Biotechnology performing? Anbio Biotechnology's latest readings are below. Over the past 13 weeks it has done worse than the S&P 500, for 23 weeks running. This describes what the data did, not a rating (as of 3 November 2026). ### Will Anbio Biotechnology's stock price go up? This page does not forecast Anbio Biotechnology's stock price. What it shows instead: the stock price is $3.58. Nobody can reliably say which way a price will move, and this site does not try (as of 3 November 2026). ### Where is Anbio Biotechnology in its business cycle? Anbio Biotechnology's FY25 operating margin was 66.7%, against a 5-year range of 24.4% to 66.7%: the top of its range, a record year. When profit is at a record, every ratio looks better than usual, and the story depends on margins staying high. The latest quarter was 59.1%. Comparing margins with a company's own long history is a good way to see where it is in its cycle (as of 3 November 2026). ### What could break the Anbio Biotechnology story? The main question: profits are rising, but only −34% of the last 3 years' profit came in as cash from operations. The gap between reported profit and actual cash is the thing to watch. On price, this page treats a rise as over when the share price closes below its 200-day average on two Fridays in a row (as of 3 November 2026). ### Is Anbio Biotechnology a stock worth studying right now? What the numbers show: Anbio Biotechnology's earnings have grown faster than its share price. Earnings per share grew +161.3% in a year while the price moved −78.8%. The main open question: whether the cash starts to follow the profit. Every number on this page is worked out by code from the published figures, with no forecasts and no price opinions (as of 3 November 2026). This is research, not advice. We’re not SEBI-registered.